Barwon Health
11
3
4
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 85/100
18.2%
2 terminated/withdrawn out of 11 trials
60.0%
-26.5% vs industry average
9%
1 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Telacebec (T) Treatment in Adults With Buruli Ulcer (BU).
Role: lead
Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.
Role: collaborator
National Robotics-Assisted Radical Prostatectomy Database
Role: collaborator
The EXCEL Registry of Patients Requiring ECMO
Role: collaborator
The Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock Trial
Role: collaborator
A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas
Role: lead
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer
Role: lead
A Pilot Study to Assess the Follow-up of Prostate Cancer Patients Who Have Undergone Radiotherapy Treatment
Role: lead
A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung Cancer
Role: lead
Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment
Role: lead
Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies
Role: lead
All 11 trials loaded